• Explore /
  • Poster
  • / LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).

LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Jens Bedke , Jose A. Karam , Rana R. McKay , Robert J. Motzer , Sumanta K. Pal , Cristina Suárez , Robert Uzzo , Hong Liu , Joseph E. Burgents , Manish Sharma , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT05239728

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4602)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4602

Abstract #

TPS4602

Poster Bd #

91a

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Toni K. Choueiri

First Author: Brandon Manley

First Author: Takahiro Tsushima